CD274 and cancer: Hypermutated cancers, such as melanomas and lung carcinomas, are extremely susceptible to immune checkpoint inhibitors (ICIs) (i.e., anti-CTLA-4 (cytotoxic T-lymphocyte antigen-4), anti-PD-1 (programmed death-1) and anti-PD-L1 (programmed death-1 ligand) antibodies) [49,50].